The bio-artificial pancreas to treat type 1 diabetes: Perspectives from healthcare professionals in the Netherlands

IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM
{"title":"The bio-artificial pancreas to treat type 1 diabetes: Perspectives from healthcare professionals in the Netherlands","authors":"","doi":"10.1016/j.jcte.2024.100372","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><div>Healthcare professionals are relevant stakeholders because of their gatekeeper role in the clinic. This study aims to explore their perspectives on the potential future clinical implementation of the bio-artificial pancreas (BAP) for people with type 1 diabetes, and suitable target groups.</div></div><div><h3>Methods</h3><div>Semi-structured interviews were conducted with 17 healthcare professionals, including endocrinologists, nurses, and pancreas transplant surgeons. Inclusion was stopped once data saturation was reached. The audiotaped interviews were transcribed verbatim. Qualitative content analysis using an inductive approach was conducted to develop themes within a coding framework.</div></div><div><h3>Results</h3><div>Three main themes emerged: (1) hoped-for benefits, which included improved clinical outcomes, enhanced sense of normality, reduced mental burden for patients and their significant others, greater societal participation, and lower costs; (2) concerns, which included safety and effectiveness, inequitable access, accurate information, control over self-management, and organizational challenges; and (3) allocating the BAP during initial implementation, which included prioritizing people who lack effective treatment options, people with mental health issues, and vulnerable people.</div></div><div><h3>Conclusions</h3><div>The results of this study are important for researchers and practitioners involved in the development of the BAP, so that they can align its design and the process of clinical implementation with healthcare professionals’ perspectives.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical and Translational Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2214623724000437","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Aims

Healthcare professionals are relevant stakeholders because of their gatekeeper role in the clinic. This study aims to explore their perspectives on the potential future clinical implementation of the bio-artificial pancreas (BAP) for people with type 1 diabetes, and suitable target groups.

Methods

Semi-structured interviews were conducted with 17 healthcare professionals, including endocrinologists, nurses, and pancreas transplant surgeons. Inclusion was stopped once data saturation was reached. The audiotaped interviews were transcribed verbatim. Qualitative content analysis using an inductive approach was conducted to develop themes within a coding framework.

Results

Three main themes emerged: (1) hoped-for benefits, which included improved clinical outcomes, enhanced sense of normality, reduced mental burden for patients and their significant others, greater societal participation, and lower costs; (2) concerns, which included safety and effectiveness, inequitable access, accurate information, control over self-management, and organizational challenges; and (3) allocating the BAP during initial implementation, which included prioritizing people who lack effective treatment options, people with mental health issues, and vulnerable people.

Conclusions

The results of this study are important for researchers and practitioners involved in the development of the BAP, so that they can align its design and the process of clinical implementation with healthcare professionals’ perspectives.
治疗 1 型糖尿病的生物人工胰腺:荷兰医疗保健专业人员的观点
目的 医护人员是相关利益方,因为他们在临床中扮演着把关人的角色。本研究旨在探讨他们对生物人工胰腺 (BAP) 未来在 1 型糖尿病患者中的潜在临床应用以及合适目标群体的看法。方法对 17 名医疗保健专业人员进行了半结构式访谈,其中包括内分泌科医生、护士和胰腺移植外科医生。一旦数据达到饱和,即停止纳入。访谈录音逐字记录。采用归纳法进行定性内容分析,在编码框架内形成主题。结果出现了三大主题:(1) 希望获得的益处,包括改善临床结果、增强正常感、减轻患者及其重要他人的精神负担、扩大社会参与以及降低成本;(2) 关注的问题,包括安全性和有效性、不公平的获取途径、准确的信息、对自我管理的控制以及组织方面的挑战;(3) 在初步实施过程中对 BAP 的分配,包括优先考虑缺乏有效治疗选择的人、有精神健康问题的人以及弱势人群。结论本研究的结果对于参与制定《最佳治疗方案》的研究人员和从业人员非常重要,这样他们就可以根据医护专业人员的观点调整方案的设计和临床实施过程。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.10
自引率
0.00%
发文量
24
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信